Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk
Background: A mean relative 50 % reduction of LDL cholesterol (LDLc) levels was observed in randomized studies in patients treated with inclisiran, a small-interfering-RNA therapeutic agent that reduces hepatic synthesis of PCSK9. Less is known on real world and every-day practice patients. Methods:...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2025-09-01
|
| Серии: | Atherosclerosis Plus |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2667089525000215 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|